Mesoblast Ltd Total Assets

Latest as of December 2025: AU$782.31 Million AUD ≈ $553.53 Million USD

Mesoblast Ltd total assets. Based on the latest financial reports, Mesoblast Ltd (MSB) holds total assets worth AU$782.31 Million AUD (≈ $553.53 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MSB stock market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Mesoblast Ltd (2005–2025)

Total assets of Mesoblast Ltd from 2005 to 2025. This chart illustrates how Mesoblast Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Mesoblast Ltd for real-time trading data and today's change.

Mesoblast Ltd - Asset Composition Analysis

Mesoblast Ltd Total Assets Breakdown (June 2025)

Mesoblast Ltd total assets breakdown as of June 2025. Mesoblast Ltd's total assets of AU$782.31 Million consist of 26.0% current assets and 74.0% non-current assets.

Asset Category	Amount (AUD)	% of Total Assets
Cash & Equivalents	AU$0.00	20.5%
Accounts Receivable	AU$14.87 Million	1.9%
Inventory	AU$22.25 Million	2.8%
Property, Plant & Equipment	AU$5.82 Million	0.7%
Intangible Assets	AU$437.37 Million	55.7%
Goodwill	AU$134.45 Million	17.1%

Asset Composition Trend (2005–2025)

This chart illustrates how Mesoblast Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MSB current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Mesoblast Ltd's current assets represent 26.0% of total assets in 2025, a decrease from 71.4% in 2005.
Cash Position: Cash and equivalents constituted 20.5% of total assets in 2025, down from 70.3% in 2005.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 3.0% in 2005.
Asset Diversification: The largest asset category is intangible assets at 55.7% of total assets.

Mesoblast Ltd Competitors by Total Assets

Key competitors of Mesoblast Ltd based on total assets are shown below.

Company	Country	Total Assets
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	USA	$1.26 Billion
Verona Pharma plc F:I9SA	Germany	€572.87 Million
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	USA	$641.76 Million
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	China	CN¥37.46 Billion
Metsera, Inc. Common Stock NASDAQ:MTSR	USA	$639.66 Million
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Bavarian Nordic CO:BAVA	Denmark	Dkr14.95 Billion
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥4.66 Billion

Mesoblast Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.58	0.96	1.72
Quick Ratio	1.41	0.63	1.72
Cash Ratio	0.00	0.00	0.00
Working Capital	AU$74.41 Million	AU$-3.07 Million	AU$71.22 Million

Mesoblast Ltd - Advanced Valuation Insights

This section examines the relationship between Mesoblast Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.76
Latest Market Cap to Assets Ratio	2.46
Asset Growth Rate (YoY)	17.3%
Total Assets	AU$784.68 Million
Market Capitalization	$1.93 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values Mesoblast Ltd's assets at a significant premium (2.46x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Mesoblast Ltd's assets grew by 17.3% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Mesoblast Ltd (2005–2025)

The table below shows the annual total assets of Mesoblast Ltd from 2005 to 2025.

Year	Total Assets	Change
2025-06-30	AU$784.68 Million ≈ $555.21 Million	+17.27%
2024-06-30	AU$669.15 Million ≈ $473.47 Million	-0.04%
2023-06-30	AU$669.41 Million ≈ $473.65 Million	+1.10%
2022-06-30	AU$662.14 Million ≈ $468.51 Million	-11.09%
2021-06-30	AU$744.72 Million ≈ $526.93 Million	+1.52%
2020-06-30	AU$733.60 Million ≈ $519.07 Million	+12.50%
2019-06-30	AU$652.12 Million ≈ $461.41 Million	-5.82%
2018-06-30	AU$692.44 Million ≈ $489.95 Million	+5.61%
2017-06-30	AU$655.69 Million ≈ $463.94 Million	-4.14%
2016-06-30	AU$684.02 Million ≈ $483.99 Million	-32.80%
2015-06-30	AU$1.02 Billion ≈ $720.25 Million	+13.19%
2014-06-30	AU$899.31 Million ≈ $636.32 Million	+1.77%
2013-06-30	AU$883.71 Million ≈ $625.28 Million	+22.66%
2012-06-30	AU$720.46 Million ≈ $509.77 Million	-5.61%
2011-06-30	AU$763.25 Million ≈ $540.05 Million	+1831.56%
2010-06-30	AU$39.51 Million ≈ $27.96 Million	+46.49%
2009-06-30	AU$26.98 Million ≈ $19.09 Million	-2.93%
2008-06-30	AU$27.79 Million ≈ $19.66 Million	+30.84%
2007-06-30	AU$21.24 Million ≈ $15.03 Million	+29.62%
2006-06-30	AU$16.38 Million ≈ $11.59 Million	-23.67%
2005-06-30	AU$21.47 Million ≈ $15.19 Million	--

About Mesoblast Ltd

AU:MSB Australia Biotechnology

Market Cap

$1.93 Billion

AU$2.72 Billion AUD

Market Cap Rank

#6093 Global

#145 in Australia

Share Price

AU$2.10

Change (1 day)

-2.78%

52-Week Range

AU$1.76 - AU$3.07

All Time High

AU$5.21